Today: 19 March 2026
Browse Category

NASDAQ:TWST 7 August 2025 - 2 February 2026

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience shares surged 14% to $46.88 Monday after posting record Q1 revenue of $103.7 million and raising its full-year forecast. Gross margin reached 52%, with net loss narrowing to $30.5 million. The company reaffirmed its target to reach adjusted EBITDA breakeven by late fiscal 2026. Investors are watching if Twist can sustain margins and meet its March-quarter revenue guidance.
Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience shares rose nearly 8% Monday after preliminary fiscal Q1 revenue reached about $103.7 million, beating company forecasts. DNA Synthesis and Protein Solutions sales climbed 27% to $51.1 million, while NGS Applications revenue hit $52.6 million. CEO Emily Leproust cited strong demand in both segments. Full audited results are due Feb. 2.
Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience shares rose about 5.4% to $34.26 midday Dec. 22, 2025, after new licensing deals and product expansions. The stock remains down roughly 26% year-to-date despite the rally. Recent catalysts include a licensing agreement with Aptamer Group for hot-start PCR and NGS products and continued integration with Element Biosciences’ AVITI system. TWST’s 52-week range spans $23.30 to $55.33.
Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience shares rose about 6% to $33 by late morning Dec. 17 after new partnership news, recent product launches, and a Barclays price target hike to $39. The company signed a licensing deal with Aptamer Group for use in PCR and NGS products and launched new plasmid DNA preps. Investors are watching progress toward breakeven targeted for fiscal Q4 2026.
DNA Drives, Glass Discs & 5D Crystals: The Race to Store Data Forever

DNA Drives, Glass Discs & 5D Crystals: The Race to Store Data Forever

DNA data storage can theoretically reach up to 1 zettabyte per gram and survive millennia, but writing remains slow and costly. In 2025, Twist Bioscience spun off Atlas Data Storage with $155 million to commercialize DNA storage, while Catalog built a fridge-sized encoder. Microsoft’s Project Silica glass discs now store up to 7 TB each, withstand extreme conditions, and are set for Azure pilots by 2026, outpacing DNA in practical deployment.

Stock Market Today

  • Arabica Coffee Prices Slip on Record Brazil Crop and High ICE Inventories
    March 19, 2026, 12:31 PM EDT. Arabica coffee futures declined by 0.63% due to expectations of a record Brazilian crop and elevated ICE (Intercontinental Exchange) inventories hitting a 5.75-month high. StoneX forecast Brazil's 2026/27 coffee production at 75.3 million bags, significantly higher than previous estimates. Conversely, robusta coffee rose 1.47% amid tighter inventories and supportive factors like disruptions at the Strait of Hormuz, which increased shipping and fuel costs for importers. Brazil's recent export declines and heavy rainfall in key growing regions have added complexity to market dynamics. Global coffee production, driven by Brazil and Vietnam, is projected to climb, pressuring prices despite some supply restraints. The International Coffee Organization noted a fall in current marketing year exports, contrasting the bullish inventory outlook for arabica.
Go toTop